Clinical Trial

Antidepressant Treatment for Depression

Study Description

Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy (ADT). Adequate ADT is defined as a therapeutically sufficient dose for a sufficient treatment period, which would be expected to be effective as listed in the MGH Antidepressant Treatment Response Questionnaire (ATRQ). Patients will be randomized in a 1:1:1 fashion to one of three open-label treatment arms: a) aripiprazole augmentation, b) rTMS augmentation, and c) switching to venlafaxine XR or Duloxetine.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Aripiprazole

Oral adjunctive therapy with aripiprazole, dose adjusted for effectiveness and tolerability.

Device - Repetitive transcranial magnetic stimulation (rTMS)

Adjunctive therapy with transcranial magnetic stimulation, dose adjusted for effectiveness and tolerability.

Drug - Venlafaxine XR

Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.

Additional Information

Official Study Title

Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD)

Clinical Trial ID

NCT02977299

ParticipAid ID

1aK2Me